skip to main content
Show Results with: Show Results with:

Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities

Gastric Cancer, 2019, Vol.22(1), pp.130-137 [Peer Reviewed Journal]

Full text available

  • Title:
    Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities
  • Author: Tanahashi, Toshiyuki ; Yoshida, Kazuhiro ; Yamaguchi, Kazuya ; Okumura, Naoki ; Takeno, Atsushi ; Fujitani, Kazumasa ; Fukushima, Norimasa ; Takiguchi, Nobuhiro ; Nishida, Yasunori ; Boku, Narikazu ; Yoshikawa, Takaki ; Terashima, Masanori
  • Found In: Gastric Cancer, 2019, Vol.22(1), pp.130-137 [Peer Reviewed Journal]
  • Subjects: Gastric cancer ; Elderly patients ; Adjuvant chemotherapy ; S-1
  • Language: English
  • Description: In Japan, S-1 adjuvant chemotherapy for 1 year is the standard of care for the treatment of stage II and III patients under 80 years old with gastric cancer after curative operation. However, the feasibility of S-1 chemotherapy in patients over 80 years old has not yet been elucidated. To clarify the current treatment situation and feasibility of S-1 treatment in patients over 80 years old, a questionnaire survey of the patients treated from January 2011 to December 2012 was conducted at 58 member institutions of the Stomach Cancer Study Group of the JCOG (Japan Clinical Oncology Group). Gastrectomy was performed in 15,573 patients of all ages, and 1,660 (10.7%) patients were over 80 years of age. Of these elderly patients, 661 (4.2%) were diagnosed as stage II and III. While S-1 adjuvant chemotherapy was recommended to 248 (37.5%) of the stageII/III patients, only 99 (15.0%) of them actually received S-1. Interestingly, the creatinine clearance rate was between 30 and 80 mL/min in 87 (87.9%) of the patients suggesting that S-1 dose modification should be considered. Moreover, S-1 compliance was poor in patients with more than 15% body weight loss. In general practice, surgery alone can be regarded as the standard of care for stage II and III gastric cancer patients over 80 years old. The feasibility and efficacy of S-1 adjuvant chemotherapy should be elucidated in a randomized control trial considering the vulnerabilities of the elderly.
  • Identifier: ISSN: 1436-3291 ; E-ISSN: 1436-3305 ; DOI: 10.1007/s10120-018-0834-x

Searching Remote Databases, Please Wait